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What’s known on the subject? and What does the study add?
• Lymph node dissection and it’s extend during robot-assisted radical cystectomy varies based on surgeon related factors.
• This study reports outcomes of robot-assisted extended lymphadenectomy based on surgeon experience in both
academic and private practice settings.
Objective
• To evaluate the incidence of, and predictors for,
extended lymph node dissection (LND) in patients
undergoing robot-assisted radical cystectomy
(RARC) for bladder cancer, as extendedLND is
critical for the treatment of bladder cancer but the
role of minimally invasive surgery for extended LND
has not been well-deﬁned in a multi-institutional
setting.
Patients and Methods
• Used the International Robotic Cystectomy Consortium
(IRCC) database.
• In all, 765 patients who underwent RARC at 17
institutions from 2003 to 2010 were evaluated for receipt
of extended LND.
• Patients were stratiﬁed by age, sex, clinical stage,
institutional volume, sequential case number, and
surgeon volume.
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• Logistic regression analyses were used to correlate
variables to the likelihood of undergoing extended LND.
Results
• In all, 445 (58%) patients underwent extended LND.
• Among all patients, a median (range) of 18 (0–74) LNs
were examined.
• High-volume institutions (100 cases) had a higher
mean LN yield (23 vs 15, P < 0.001).
• On univariable analysis, surgeon volume, institutional
volume, and sequential case number were associated with
likelihood of undergoing extended LND.
• On multivariable analysis, surgeon volume [odds ratio
(OR) 3.46, 95% conﬁdence interval (CI) 2.37–5.06,
P < 0.001] and institution volume [OR 2.65, 95% CI
1.47–4.78, P = 0.001) were associated with undergoing
extended LND.
Conclusions
• Robot-assisted LND can achieve similar LN yields to
those of open LND after RC.
• High-volume surgeons are more likely to perform
extended LND, reﬂecting a correlation between their
growing experience and increased comfort with
advanced vascular dissection.
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Introduction
Open radical cystectomy (RC) with pelvic lymph node
dissection (LND) is the standard of care for treatment
of invasive carcinoma of the bladder [1]. Regional LND
may not only be diagnostic, but also therapeutic, in
patients with locally advanced bladder cancer [2]. Studies
have suggested up to a 36% improvement in 5-year
survival in patients who underwent LND in limited
nodal disease [3]. About 25% of patients will have
pathological evidence of LN metastases at the time of RC
[4–6]. Many analyses since then have suggested that
cancer-speciﬁc and recurrence-free survival depend
on the extent of surgical removal of local and regional
disease [4].
Robot-assisted RC (RARC) has developed as a minimally
invasive alternative to open RC for invasive bladder cancer
[7–9].While RA surgery becomes incorporated into
urological oncology, there is still lack of data on
oncological outcomes, including LN yield, surgical margins,
and long-term survival after RARC [10].
In an eﬀort to establish standards for surgical quality,
Herr and the Bladder Cancer Collaborative Group [11]
proposed standards for RC and LND, including a median
of 10–14 LNs retrieved. There is data to indicate that the
performance and LN yield of LND in RC are improving
signiﬁcantly over time [12]. Several studies suggest
diﬀerent thresholds for LN yield to prolong survival
in the open RC literature [13]. Preliminary data have
shown that comparable LN yields can be achieved in
RARC [14,15]. Studies also show that a learning curve
exists for LN yield [16] and the likelihood of receiving
LND [14]. Single-institution series of RARC reported a
high likelihood of patients receiving extended LND
[17,18], but these results have not been reported in
multi-institutional series. Therefore, we retrospectively
studied a multi-institutional, prospectively maintained,
international database to identify the LN yield,
incidence of, and predictors for, extended LND in
patients undergoing RARC for locally invasive bladder
cancer.
Patients and Methods
The present study was a retrospective review of the
prospectively maintained Institutional Review
Board-approved database (I 97906) of the International
Robotic Cystectomy Consortium (IRCC), the database
encompasses a mixture of academic and private centres
comprising patients treated with RARC for clinically
localised bladder cancer from 2003 to 2010.
Clinical and pathological data were available from 765
patients who underwent RARC by one of 43 surgeons at 17
institutions. Patients in the group ranged in age from 28 to
90 years of age and 161 (21%) were women. Clinical
features evaluated included age, gender, pathological stage,
surgeon volume, institution volume, sequential case
number, LN status, and LN yield.
LNs were evaluated according to the routine pathological
methods at the participating institutions. Centralised review
of pathology was not performed. Patients were divided into
two groups for further analysis; those who underwent
extended LND and those who underwent either standard
or no LND. Institutions were surveyed about boundaries of
the standard and extended LND, which are reported in
Table 1. All pathological specimens were reviewed by
individual institutional pathologists using the American
Joint Committee on Cancer TNM staging system relevant
to the time of diagnosis.
The primary outcome measures were the incidence of and
predictors for extended LND in patients undergoing
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RARC. Groups were deﬁned by gender, age groups (60,
61–70, 71–80,81 years), preoperative T stage (T1 or
carcinoma in situ, T2,T3), pathological T stage (T2, T3,
T4), case number (1–10, 11–25, 26–50,51), surgeon
volume (1–10, 11–50,51), institution volume (100 or
>100), and LN status (positive or negative).
Logistic regression analyses were used to evaluate
predictors of undergoing an extended LND. Variables that
were signiﬁcantly associated (P < 0.05) with the likelihood
of undergoing extended LND on univariable analysis were
included in the multivariable model.
Results
In all 765 patients, who underwent RARC and had data on
extent of LND, were included in this study. The mean
(range) age was 67 (28–90) years and 161 patients (21%)
were female. In all, 316 of patients (46%) had an American
Society of Anesthesiologists score of 3. The mean (range)
operative duration was 421 (157–862) min, the mean
(range) estimated blood loss was 479 (50–3900) mL, and
the median (interquartile range) hospital stay was 8 (6–13)
days. In all, 445 patients (58%) underwent extended LND,
304 patients (40%) underwent standard LND, and 16
patients (2%) did not undergo LND. The mean (range) LN
yield was 18 (0–74). In all, 596 patients (78%) underwent
LND (LN yield  10) as deﬁned by Herr et al. [11].When
stratiﬁed by type of LND, 68% and 88% of patients
underwent standard and extended LND, respectively, and
had 10 LNs removed. Overall, 198 patients (27%) had
positive LNs. In all, 311 patients (41%) had a pathological
stage of pT3. In extended LND, the mean LN yield was
21 and in standard LND, the mean LN yield was 13 (P <
0.001; Table 2). In all, 90 patients (52%) who had continent
diversion had an extended LND vs 353 (61%) of those who
had an ileal conduit. Meanwhile, 66% and 65% of patients
who had intracorporeal and extracorporeal diversion,
respectively, had an extended LND.
The performance of extended LND was signiﬁcantly
associated with sequential case number, surgeon volume,
and institution volume (Table 3). By the 51st case, patients
were 4.4-times more likely to undergo extended LND (95%
CI 2.86–6.93, P < 0.001). High-volume surgeons (>50 cases)
were 9.5-times more likely to perform an extended LND
(95% CI 4.50–20.2, P < 0.001). High-volume institutions
(100 cases) were almost 10-times more likely to perform
an extended LND (95% CI 6.07–16.6, P < 0.001).
On multivariable analysis, institutional volume and
sequential case number remained as signiﬁcant predictors
of extended LND (Table 4). High-volume institutions
(100 cases) were 3.46-times more likely to perform
extended LND.
Discussion
Regional LND at the time of RC has been shown to
enhance local disease control, prevent local recurrence, and
improve overall survival [3]. Studies have shown that
removing more LNs improves overall survival and also
correlates with a higher LN positivity rate [4]. This leads to
more accurate staging and can guide adjuvant treatment. In
a multi-institutional study of open RC, 9% of patients had
no LNs removed during RC, and 37% had a limited LND
(obturator region only) [19]. In the present series, 26
Table 1 Institution reported boundaries of LND*.
Region Standard LND Extended LND
Obturator Yes Yes
Hypogastric Yes Yes
External iliac (up to crossing
of ureter)
Yes Yes
Common iliac No Yes
Up to aortic bifurcation No Yes
Above the inferior mesenteric artery No 1/19 institutions
Presacral No 10/19 institutions
*Two institutions did not provide details on LND deﬁnitions.
Table 2 The patients' characteristics.
Variable Value
Age, years:
Mean (SD) 67 (11)
Median (range) 67 (26–90)
BMI, kg/m2:
Mean (SD) 27.5 (5.2)
Median (range) 27 (13.6–48)
ASA score:
Mean (SD) 2.4 (0.7)
3, n (%) 316 (46)
N (%):
Prior abdominal surgery 326 (49)
Preoperative chemotherapy 76 (13)
Preoperative radiation 13 (2)
Clinical stage:
Ta, Tis 47 (8)
T1 156 (26)
T2 405 (66)
Pathological tumour stage:
pT0 83 (11)
Organ-conﬁned 361(47)
Extravesical 311 (42)
No. positive LNs 198 (27)
Overall LN yield:
Mean (SD) 18 (11)
Median (range) 16 (0–74)
Standard LND:
Mean (SD) 13 (8)
Median (range) 13 (0–54)
Extended LND:
Mean (SD) 21 (11)
Median (range) 20 (1–74)
Extended lymphadenectomy with RARC
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patients (3.4%) had no LNs removed or had no data about
LN yield, and 78% of patients underwent LND (deﬁned as
10 LNs removed).
Previous data from the IRCC on RARC and LND reported
that the median LN yield was 17 and that 83% of patients
underwent LND (deﬁned as a LN yield of 10) [14]. Since
then, six institutions and >700 patients have been added to
the IRCC database. In addition, data about the extent of
LND was obtained. Data about the extent of LND was
available for 765 patients, of whom 455 (58%) underwent
extended LND. Given the multi-institutional nature of the
IRCC, a survey regarding boundaries of LND was sent to
all IRCC institutions (Table 1). All responding institutions
deﬁned an extended LND as extending at least up to the
aortic bifurcation  the presacral LNs.
The mean number of LNs removed in the present series
was 18. This is similar to large open RC series, where mean
LN counts have ranged from 14 to 40 [20,21]. In our IRCC
data, the mean number of LNs removed was 13 and 21 in
standard and extended LND, respectively. This compares
favourably to the collaborative group report by Herr et al.
[11], which reported a mean LN yield of 13 and 26 for
standard and extended LND, respectively. Nix et al. [15]
reported no diﬀerence in mean LN yield between open RC
and RARC (18 vs 19 LNs, respectively) in a prospective
randomised single-centre non-inferiority study. Recently,
Davis et al. [22] performed a second-look open LND by
expert surgeons after completion of RALND. They reported
that 80% of patients had either no residual tissue or some
residual tissue without identiﬁcation of LNs despite lengthy
procedure times taken to search for LN tissue.
We found that the performance of an extended LND was
signiﬁcantly associated with surgeon volume and
institution volume. On multivariable analysis, each increase
in surgeon volume (1–10, 11–50, and 51 cases) was
associated with a 3.5-fold increase in the likelihood of
undergoing extended LND. This ﬁnding became more
striking if the surgeon volume was stratiﬁed using a case
Table 3 Extended vs no/standard pelvic LND.
No/standard
pelvic LND, n (%)
Extended
pelvic LND, n (%)
Total,
n (%)
OR (95% CI) P
Age group, years:
60 94 (29) 120 (27) 214 (28) Reference 1.0
61–70 108 (34) 147 (33) 255 (33) 1.07 (0.74–1.54) 0.732
71–80 98 (31) 135 (30) 233 (31) 1.08 (0.74–1.57) 0.691
81 19 (6) 41 (9) 60 (8) 1.69 (0.92–3.10) 0.090
Sex:
Male 259 (81) 345 (78) 604 (79) Reference 1.0
Female 61 (19) 100 (22) 161 (21) 1.23 (0.86–1.76) 0.254
Preoperative T stage:
T1 or CIS 103 (37) 100 (30) 203 (33) Reference 1.0
T2 142 (52) 197 (59) 338 (56) 1.43 (1.01–2.03) 0.045
T3 30 (11) 36 (11) 66 (11) 1.24 (0.71–2.16) 0.456
Case number:
1–10 85 (26) 67 (15) 152 (20) Reference 1.0
11–25 98 (31) 95 (21) 193 (25) 1.23 (0.82–1.97) 0.342
26–50 84 (26) 97 (22) 181 (24) 1.46 (0.95–2.26) 0.084
51 53 (17) 186 (42) 239 (31) 4.45 (2.86–6.93) <0.001
Surgeon volume, n:
1–10 19 (7) 29 (7) 48 (7) Reference 1.0
11–50 230 (86) 153 (34) 383 (54) 0.44 (0.24–0.80) 0.008
51 18 (7) 262 (59) 199 (39) 9.53 (4.50–20.2) <0.001
Institution volume, n:
100 298 (92) 259 (58) 557 (73) Reference 1.0
101 22 (7) 186 (42) 208 (27) 9.72 (6.07–16.60) <0.001
Pathological stage:
T2 197 (63) 247 (56) 444 (59) Reference 1.0
T3 79 (25) 146 (33) 225 (30) 1.47 (1.06–2.05) 0.022
T4 37 (12) 49 (11) 86 (11) 1.05 (0.66–1.68) 0.818
LN status:
Negative 228 (75) 320 (72) 548 (73) Reference 1.0
Positive 75 (25) 123 (28) 198 (27) 1.16 (0.84–1.63) 0.360
Table 4 Multivariable analysis – predictors of extended LND.
Variable OR (95% CI) P
Surgeon volume 3.46 (2.37–5.06) <0.001
Institutional volume 2.65 (1.47–4.78) 0.001
Sequential case number 1.15 (0.96–1.38) 0.120
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number of 50 as a threshold (i.e. volume 1–50 vs 51). In
this analysis, high-volume surgeons were 20- and 36-times
more likely to perform extended LND on univariable and
multivariable analysis, respectively (data not shown). This
ﬁnding is similar to large open RC series, in which
high-volume surgeons usually have improved outcomes
over low-volume surgeons [23].
Receipt of an extended LND was signiﬁcantly associated
with high-volume institutions (101 cases). On
multivariable analysis, high-volume institutions were
>2.5-times more likely to perform extended LND than
low-volume institutions. Similar ﬁndings have been
validated in large multi-institution open RC series [24].
This can be explained by the fact that high-volume
institutions probably have the experience, and availability of
services, to be able to carry out a complex operation. In
addition, it intuitively makes sense that high-volume
surgeons are more likely to operate at high-volume
institutions.
LN yield can vary based on pathological evaluation. The
method by which LNs are submitted for pathological
review can aﬀect the number of reported LNs (en bloc vs
separate packets) [21]. Pathological evaluation was not
centralised within the IRCC, and the method of submitting
LNs to pathology was not captured in the IRCC database.
The present study is the ﬁrst of its kind with a large overall
cohort comparable with contemporary open series. The
present study has limitations inherent to the retrospective
and observational data approach. First, due to the many
surgeons and variability of practice type and location
involved in this cohort, selection and reporting bias may
have been present that could aﬀect the results. Second,
review of operative data was not centralised, and there was
probably variability in specimen review. In addition,
pathological evaluation was not centralised in the present
cohort. Third, the number of patients varied widely among
the 17 institutions studied. The outcomes from this cohort
may have been inﬂuenced by institutions with higher
volumes.
In conclusion, RA extended LND is feasible and follows the
oncological principles of open extended LND. High-volume
institutions and higher surgeon volume signiﬁcantly
predicted the performance of an extended LND in the
present cohort.
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